HIIFS
BIO icon

Harel Insurance Investments & Financial Services’s Bio-Rad Laboratories Class A BIO Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-332
Closed -$634K – 773
2021
Q1 		$634K Buy
332
+28
+9% +$16.6K 0.01% 466
2020
Q4 		$570K Hold
304
– – 0.01% 346
2020
Q3 		$157K Buy
+304
New +$154K 0.01% 334

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harel Insurance Investments & Financial Services's BIO Position: Q2 2021 in Review

Harel Insurance Investments & Financial Services sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2021, closing a stake of 332 shares — an estimated $634K sold.

Harel Insurance Investments & Financial Services first reported a position in BIO in Q3 2020 and held it in 3 quarters. The position peaked at $634K in Q1 2021. 509 funds tracked by Wall St. Rank hold BIO as of Q2 2021.

  • Harel Insurance Investments & Financial Services reported no remaining Bio-Rad Laboratories Class A position as of Q2 2021 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 332 Bio-Rad Laboratories Class A shares in Q2 2021, an estimated $634K.
  • Harel Insurance Investments & Financial Services first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 3 quarters.
  • Harel Insurance Investments & Financial Services's Bio-Rad Laboratories Class A position peaked at $634K in Q1 2021.
  • 509 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2021.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2021, filed 26 Jul 2021.